Nanofármacos

COMPOSITIONS AND METHODS OF USING GENE CODING FOR TREATING OCULAR DISEASE

Resumen de: WO2025188836A1

The present disclosure describes methods of using lipid nanoparticle (LNP) compositions for treating ocular- related disorders or diseases. In particular, methods are provided for using LNP compositions in gene therapy for targeting an ATP binding cassette subfamily A member 4 (ABCA4) or a functional fragment thereof, in a subject, thereby treating or mitigating Inherited Macular Degenerations including a Stargardt disease or other diseases that involve retinal degeneration.

NEW METHOD FOR DELIVERING COMPOUNDS OF INTEREST

Resumen de: WO2025188185A1

The present invention provides a delivery system comprising of a first aqueous composition harbouring small particles and a second aqueous composition harbouring larger particles in which the particles of the first and second aqueous compositions may comprise the same or a different compound of interest, wherein said compound of interest preferably is a hydrophobic or amphiphilic compound. In both cases the small particles comprise a partly liquid oil phase at temperatures around about 4°C.

POLYMER MODIFIED NANOPARTICLES FOR CYTOKINE OR OTHER PAYLOAD DELIVERY

Resumen de: WO2025188498A1

Disclosed herein are cytokine constructs that include a delivery vehicle, and at least one cytokine or one decoy receptor. By adjusting the types and density of cytokines on the constructs, they can be tailored for both local and systemic treatment of patients with cancers and other immune-related diseases, such as autoimmune diseases. Additionally, the cytokine constructs can be used ex vivo to expand and activate cells from patients or healthy subjects before re-infusing the activated cells back into patients, which benefits adoptive and stem cell therapies. These constructs display improved half-life and stability of cytokines, enabling reducing doses, and minimizing toxicity from unintended effects of free cytokines. Furthermore, the constructs allow for co-delivery of other therapeutics, such as antibodies, small molecule inhibitors, chemotherapeutics, oligonucleotides, adjuvants, and antigens.

METHOD FOR MANUFACTURING POROUS SILICON NANOPARTICLES BY MEANS OF ULTRASONIC TREATMENT

Resumen de: WO2025188061A1

The present invention relates to a method for manufacturing porous silicon nanoparticles by means of ultrasonic treatment. A novel ultrasonic treatment apparatus using a duty cycle scheme was fabricated, and physical properties such as optimized conditions of the apparatus, yield, size, size distribution, surface state, shape, pore size, and drug delivery capacity of the porous silicon nanoparticles manufactured by the duty cycle scheme were analyzed. The duty cycle scheme was confirmed to exhibit a significantly higher yield of porous silicon nanoparticles compared to conventional schemes, and the porous silicon nanoparticles manufactured by the duty cycle scheme exhibited similar physical properties to those of porous silicon nanoparticles manufactured by the conventional schemes. Therefore, it was confirmed that the method for manufacturing porous silicon nanoparticles by means of ultrasonic treatment using the duty cycle scheme of the present invention is suitable for mass production.

LIPID NANOPARTICLE

Resumen de: WO2025187760A1

The purpose of the present invention is to provide a lipid nanoparticle that makes it possible to efficiently introduce a drug into a cell, and a constituent lipid of this lipid nanoparticle. Provided are: a compound represented by general formula (I), (II), or (III); a salt or stereoisomer thereof; and a lipid nanoparticle containing the same as a constituent lipid.

POLYSACCHARIDE COMPOSITION, NANO POLYSACCHARIDE, PREPARATION METHOD THEREFOR, AND USE THEREOF

Resumen de: WO2025185570A1

A polysaccharide composition, a nano polysaccharide, a preparation method therefor, and use thereof. The polysaccharide composition comprises a polysaccharide and a lipid material. The weight ratio of the polysaccharide to the lipid material is 2-50:1.

IRON-OXIDE NANOPARTICLE-LOADED MESENCHYMAL STEM CELLS AND USES THEREOF

Resumen de: WO2025184767A1

A composition that includes a stem cell and a coated iron oxide nanoparticle. The coated iron oxide nanoparticle, being present in the cytoplasm of the stem cell, contains a superparamagnetic iron oxide core that is coated with one or more biocompatible polymers, each of which has a polyethylene glycol group, a silane group, and a linker covalently linking the polyethylene glycol group and the silane group. Also provided is a method for treating an inflammatory disorder in which stem cells are cultured in the presence of coated iron oxide nanoparticles and the cultured stem cells are administered to a subject suffering from an inflammatory disorder. Further disclosed is a method for tracking stem cells in vivo by labeling stem cells with coated iron oxide nanoparticles, administering the labeled stem cell to an individual, and obtaining one or more T2 weighted magnetic resonance images of the individual to track the stem cells.

LIPID NANOPARTICLE COMPOSITIONS INCORPORATING AN IMMUNOSUPPRESSANT FOR THE DELIVERY OF SELF-AMPLIFYING RNA

Resumen de: WO2025184750A1

A lipid nanoparticle composition for use in the delivery of a self-amplifying RNA (saRNA) construct in one or more target cells is disclosed. The lipid nanoparticle composition comprises a lipid mixture comprising at least one (ionizable) cationic lipid, at least one helper lipid, a sterol, a corticosteroid such as Dexamethasone, and a least one lipid-polyethylene glycol conjugate. The saRNA construct comprises a first open reading frame which encodes one or more non-structural proteins, and a second open reading frame operatively linked to the first open reading frame. The second open reading frame comprises a coding region which encodes one or more target proteins. In some embodiments, the target proteins comprise one or more therapeutic proteins. In some embodiments, the target proteins comprise one or more one or more Cas proteins and/or variants thereof for use in CRISPR-based gene editing.

NANOPARTICLES AND USES THEREOF

Resumen de: WO2025184694A1

The present disclosure relates generally to nanoparticles and compositions comprising the same, and their use for transfecting transfection-recalcitrant cells, wherein the nanoparticle is tethered to an antigen-binding moiety having binding specificity for an antigen expressed on the surface of the cell, such as cluster of differentiation 2 (CD2) or cluster of differentiation 7 (CD7), wherein the nanoparticle comprises at least an ionisable lipid and a sterol.

一种仿生纳米囊泡及其制备方法和应用

Resumen de: CN120617207A

本发明公开了一种仿生纳米囊泡制备方法，包括以下步骤：将表没食子茶素没食子酸酯和硒代蛋氨酸溶于去离子水中，加入甲醛溶液在黑暗环境中搅拌，离心纯化，得球形纳米颗粒；从干细胞中提取外泌体；将球形纳米颗粒与外泌体加入去离子水中搅拌得仿生纳米囊泡。本发明制备的仿生纳米囊泡可对巨噬细胞和T细胞的进行调控，具有抗炎和调控免疫网络作用，应用于对急性肾损伤的保护作用。

一种能够控制纳米颗粒尺寸与球形度的制备方法

Resumen de: CN120617209A

本发明涉及一种能够控制纳米颗粒尺寸与球形度的制备方法，包括如下步骤：1）首先将乙醇溶液添加到牛血清白蛋白中进行去溶剂化得到原料液，再将原料液与适量乙醇、适量戊二醛合并成待处理溶液；2）待处理溶液转移至倾斜放置的涡旋流体装置中以转速n旋转时间T得到处理液；3）将处理液离心、洗涤后得到所述纳米颗粒。通过对涡旋流体装置轴线与水平位置的夹角、处理时间、旋转速度等多参数协同调控，实现了对牛血清白蛋白纳米颗粒的尺寸、形貌，以及球形度的精准控制，可灵活制备不同尺寸、孔径及比表面积的纳米颗粒，满足肿瘤靶向、疫苗载体等多场景需求。

一种明胶-透明质酸可注射水凝胶携载药纳米颗粒复合材料及其制备方法和应用

Resumen de: CN120617149A

本发明公开了一种明胶‑透明质酸可注射水凝胶携载药纳米颗粒复合材料及其制备方法和应用，涉及生物医学技术领域，解决现有技术中现有软骨相关疾病治疗用药物递送难，不能同时有效控制关节腔内的慢性炎症反应并保护软骨细胞，限制了药物的应用效果的技术问题。本发明制备方法，包括S1、获得肌肽修饰的透明质酸衍生物Car‑HA；S2、制备负载非诺贝特的纳米颗粒FNPs；S3、将含FNPs的明胶溶液与Car‑HA溶液混合，向上述混合体系中加入转谷氨酰胺酶，进行酶促交联反应，形成稳定网络结构的水凝胶FNPs‑GelHA。本发明所提出的Car‑HA与FNPs协同水凝胶策略具有良好的结构可调性和药物适应性，适用于多种抗炎、抗氧化、软骨修复类药物的递送，可广泛应用于软骨相关疾病的局部精准治疗。

一种脂滴仿生纳米粒子药物递送系统及其制备方法和应用

Resumen de: CN120617202A

本发明提供一种脂滴仿生纳米粒子药物递送系统及其制备方法和应用。该脂滴仿生纳米粒子药物递送系统的尺寸在纳米级别，符合有效纳米医学应用的标准，增强组织渗透和细胞吸收；水溶性良好，可应用于临床牙周炎的药物注射治疗，现配现用；具有低细胞毒性和良好的生物相容性。

基于pH响应型纳米微胶囊的白酒功能强化系统及制备方法

Resumen de: CN120624157A

本发明涉及食品工程技术领域，尤其涉及一种基于pH响应型纳米微胶囊的白酒功能强化系统及制备方法。包括：活性核、包裹于活性核外侧的pH响应壁材和包覆于壁材外侧的表面修饰层，活性核为葛根素与L‑半胱氨酸通过Zn2+螯合形成的复合物；pH响应壁材为阳离子型壳聚糖溶液与阴离子型海藻酸钠溶液通过静电逐层自组装形成的至少3层复合屏障；表面修饰层为包覆于壁材外层的β‑环糊精；所述纳米微胶囊在52％vol乙醇中储存30天的粒径增长≤5％，在pH1.2胃液中3小时释放率≥80％，在白酒体系中透光率>95％，具有良好的应用前景。

新颖的聚甘油缀合脂质和包含其的脂质纳米颗粒组合物

Resumen de: AU2023406321A1

The present disclosure provides novel polymer-conjugated lipids, e.g., comprising DODA conjugated to a polyglycerol or a polyglycerol derivative. The present disclosure also provides lipid nanoparticles (LNPs) formulation using the polymer-conjugated lipids and methods of treating a disease by administering the LNP formulations.

一种级联靶向膜包被纳米材料及其应用

Resumen de: CN120617200A

本发明公开了一种级联靶向膜包被纳米材料及其应用，属于生物医药领域。所述级联靶向膜包被纳米材料包括负载药物的介孔聚多巴胺核心和包被于所述核心外的肿瘤细胞膜；所述核心表面经TAT肽修饰；所述肿瘤细胞膜经cRGD肽修饰。所述药物为顺铂和奥拉帕尼。本发明提供的级联靶向膜包被纳米材料能有效诱导耐药肿瘤细胞的凋亡，提高了化疗治疗的效果，并逆转了骨肉瘤的化疗耐药，为骨肉瘤的精准治疗提供了新的策略和方向。

一种纳米颗粒、含其的缓释水凝胶及其超声系统和应用

Resumen de: CN120617501A

本发明公开一种纳米颗粒、含其的缓释水凝胶及其超声系统和应用，本发明所述纳米颗粒由六水合硝酸锌和二甲基咪唑形成金属有机骨架封装血卟啉单甲醚和表达ZBP1的质粒形成。本发明的超声调控多功能水凝胶平台通过超声实现ROS释放的精确控制以达到双重治疗效果，同时协同关键基因调控以及微环境的改善，应对乳腺癌骨转移中的肿瘤治疗与骨再生问题。本发明开发了一种具有生物安全性的水凝胶负载的MOF多功能系统，具有优异的抗肿瘤和促进骨修复的双重效果，具有原位注射性和缓释型，治疗成分在靶区域得到高度集中，从而显著提高了疗效并降低了副作用。

一种血管内皮靶向的仿生纳米颗粒及制备方法和应用

Resumen de: CN120617203A

本发明属于生物医药技术领域，涉及一种血管内皮靶向的仿生纳米颗粒及制备方法和应用，仿生纳米颗粒的制备方法为：(1)将STM2457溶解后加入NH2‑MSN避光搅拌，得STM@MSN；(2)将STM@MSN与金刚烷羧酸加入DMF中，得ade‑MSN；(3)将ade‑MSN加入PBS缓冲液中，加入β‑CD搅拌，得STM2457@CD‑ade‑MSN；(4)将脂质体与血小板膜混合，加入步骤(3)产物，得STM2457@CD‑ade‑MSN/PL；(5)将步骤(4)产物与还原CD31抗体混合，得到仿生纳米颗粒。本发明制备的血管内皮靶向的仿生纳米颗粒可用于预防、缓解或/和治疗化疗药物引起的心血管毒性。

一种包载辛伐他汀的茶叶外泌体样囊泡及其制备方法

Resumen de: CN120617377A

本发明公开了一种包载辛伐他汀的茶叶外泌体样囊泡及其制备方法，包载辛伐他汀的茶叶外泌体样囊泡包括：辛伐他汀，包载辛伐他汀的茶叶外泌体样囊泡；茶叶外泌体样囊泡由茶鲜叶和PEG6000溶液制备成；本发明通过茶叶外泌体样囊泡包载辛伐他汀实现他汀类药物的靶向递送降低他汀类药物的毒副作用，且惊喜的发现茶叶外泌体样囊泡包载辛伐他汀在提高降脂效果上具有协同作用。

一种阿布昔替尼纳米粒、纳米乳膏剂以及制备方法

Resumen de: CN120617208A

本发明涉及药物制剂技术领域，提供了一种阿布昔替尼纳米粒、纳米乳膏剂以及制备方法。本发明提供的阿布昔替尼纳米粒的制备原料包括阿布昔替尼、胆酸类化合物、磷脂和pH值调节剂；所述纳米乳膏剂包括阿布昔替尼纳米粒和乳剂型基质，其中乳剂型基质的成分包括水、油性基质、乳化剂、透皮吸收促进剂、增稠剂、保湿剂和防腐剂。本发明将阿布昔替尼纳米化，能够提高药物的溶解度，利用其制备的阿布昔替尼纳米乳膏剂稳定性好，药物溶解度和透皮吸收效率高，适用于特应性皮炎等皮肤炎症性疾病的局部治疗；本发明的纳米乳膏剂克服了传统纳米乳对处方比例的限制，药物用量比例有很大的调整空间，更有利于工业化生产。

阳离子脂质与脂质纳米颗粒

Resumen de: WO2024156291A1

Disclosed is a cationic lipids and salts thereof (e.g., pharmaceutically acceptable salts thereof), and compositions comprising such lipids useful for the delivery of biologically active agents.

一种纳米递药平台及其制备方法和应用

Resumen de: CN120617205A

本发明公开了一种纳米递药平台及其制备方法和应用，所述纳米递药平台是通过在羧基化的介孔二氧化硅纳米粒(MSN)表面修饰聚乙烯亚胺得到MCP纳米颗粒，然后在MCP纳米颗粒上装载药物后最后沉积丙烯酸树脂在材料表面得到。本发明通过多种材料的协同作用，实现了结肠靶向的药物治疗和炎症因子清除等多种功能的集成，并且在动物模型上取得了显著的治疗效果。

呼吸道合胞病毒疫苗及其制备方法和应用

Resumen de: EP4600256A1

The present disclosure relates to an immunological composition comprising or encoding a human respiratory syncytial virus antigen, and the immunological composition is selected from a nucleic acid immunological composition, a polypeptide immunological composition or a viral immunological composition.

一种HPV重组蛋白治疗疫苗的制备方法与应用

Resumen de: CN120617495A

本发明涉及一种HPV重组蛋白治疗疫苗的制备方法与应用，属于生物医药技术领域，所述的HPV重组蛋白治疗疫苗的制备方法包括：将多种脂质制备而成的复合脂质纳米颗粒同时包裹递送HPV16HPV E6E7重组蛋白抗原及核酸类TLR激动剂佐剂分子。本申请制得的重组蛋白治疗疫苗有利于诱导针对HPV16E6E7抗原强大的T细胞免疫反应，杀伤被HPV感染的宫颈癌细胞。此外，不同于递送mRNA疫苗的脂质纳米粒子(LNP)，配方中不存在阳离子或可离子化脂质，安全性明显高于mRNA疫苗，具有比mRNA治疗疫苗更大的优势，且毒副作用低、疫苗效果稳定。

一种用于脓毒症治疗的双重调控药物组合、制备方法和应用

Nº publicación: CN120617285A 12/09/2025

Solicitante:

沈阳药科大学

Resumen de: CN120617285A

一种用于脓毒症治疗的双重调控药物组合、制备方法和应用，属于生物医药技术领域，该药物组合包括多柔比星脂质体、全反式维甲酸磷脂复合物纳米粒及抗生素。优选由唾液酸修饰的多柔比星脂质体、唾液酸修饰的全反式维甲酸磷脂复合物纳米粒及美罗培南组成。通过对脓毒症中后期髓源性抑制细胞MDSCs和唾液酸结合免疫球蛋白型凝集素‑E(Siglec‑E)阳性表达的髓源性抑制细胞即Siglec‑E+MDSCs细胞亚群的动态监测作为免疫抑制状态的评价指标，实现对脓毒症急性炎症与免疫抑制的双重调控。本发明方法在提升生存率、精准靶向免疫抑制、改善药物递送效率等方面具有显著优势，为脓毒症的临床治疗提供了全新解决方案。